Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all NMO patients and the target of the autoimmune response in these patients is unknown. Since recent...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroinflammation Vol. 8; no. 1; p. 184
Main Authors Mader, Simone, Gredler, Viktoria, Schanda, Kathrin, Rostasy, Kevin, Dujmovic, Irena, Pfaller, Kristian, Lutterotti, Andreas, Jarius, Sven, Di Pauli, Franziska, Kuenz, Bettina, Ehling, Rainer, Hegen, Harald, Deisenhammer, Florian, Aboul-Enein, Fahmy, Storch, Maria K, Koson, Peter, Drulovic, Jelena, Kristoferitsch, Wolfgang, Berger, Thomas, Reindl, Markus
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 28.12.2011
BioMed Central
BMC
Subjects
Adolescent
Adult
Aquaporin 4 - immunology
aquaporin-4
autoantibodies
Autoantibodies - blood
Autoantibodies - immunology
Autoantigens - immunology
Autoimmunity
biomarker
Child, Preschool
Complement Activation - immunology
complement mediated cytotoxicity
Development and progression
Experiments
Female
Humans
Immunoglobulin G
Immunoglobulin G - blood
Immunoglobulin G - immunology
Male
Middle Aged
Multiple sclerosis
Myelin proteins
Myelin Proteins - immunology
Myelin-Oligodendrocyte Glycoprotein
Myelitis, Transverse - blood
Myelitis, Transverse - immunology
Neuromyelitis optica
Neuromyelitis Optica - blood
Neuromyelitis Optica - immunology
Pediatrics
Physiological aspects
Proteins
Scanning electron microscopy
Statistical analysis
Studies
Austria
Online AccessGet full text
ISSN1742-2094
1742-2094
DOI10.1186/1742-2094-8-184

Cover

Abstract Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all NMO patients and the target of the autoimmune response in these patients is unknown. Since recent studies indicate that autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) can induce an NMO-like disease in experimental animal models, we speculate that MOG might be an autoantigen in AQP4-IgG seronegative NMO. Although high-titer autoantibodies to human native MOG were mainly detected in a subgroup of pediatric acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) patients, their role in NMO and High-risk NMO (HR-NMO; recurrent optic neuritis-rON or longitudinally extensive transverse myelitis-LETM) remains unresolved. We analyzed patients with definite NMO (n = 45), HR-NMO (n = 53), ADEM (n = 33), clinically isolated syndromes presenting with myelitis or optic neuritis (CIS, n = 32), MS (n = 71) and controls (n = 101; 24 other neurological diseases-OND, 27 systemic lupus erythematosus-SLE and 50 healthy subjects) for serum IgG to MOG and AQP4. Furthermore, we investigated whether these antibodies can mediate complement dependent cytotoxicity (CDC). AQP4-IgG was found in patients with NMO (n = 43, 96%), HR-NMO (n = 32, 60%) and in one CIS patient (3%), but was absent in ADEM, MS and controls. High-titer MOG-IgG was found in patients with ADEM (n = 14, 42%), NMO (n = 3, 7%), HR-NMO (n = 7, 13%, 5 rON and 2 LETM), CIS (n = 2, 6%), MS (n = 2, 3%) and controls (n = 3, 3%, two SLE and one OND). Two of the three MOG-IgG positive NMO patients and all seven MOG-IgG positive HR-NMO patients were negative for AQP4-IgG. Thus, MOG-IgG were found in both AQP4-IgG seronegative NMO patients and seven of 21 (33%) AQP4-IgG negative HR-NMO patients. Antibodies to MOG and AQP4 were predominantly of the IgG1 subtype, and were able to mediate CDC at high-titer levels. We could show for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IgG mediated immune response, whereas MOG is not a target antigen in cases with an AQP4-directed humoral immune response.
AbstractList Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all NMO patients and the target of the autoimmune response in these patients is unknown. Since recent studies indicate that autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) can induce an NMO-like disease in experimental animal models, we speculate that MOG might be an autoantigen in AQP4-IgG seronegative NMO. Although high-titer autoantibodies to human native MOG were mainly detected in a subgroup of pediatric acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) patients, their role in NMO and High-risk NMO (HR-NMO; recurrent optic neuritis-rON or longitudinally extensive transverse myelitis-LETM) remains unresolved. We analyzed patients with definite NMO (n = 45), HR-NMO (n = 53), ADEM (n = 33), clinically isolated syndromes presenting with myelitis or optic neuritis (CIS, n = 32), MS (n = 71) and controls (n = 101; 24 other neurological diseases-OND, 27 systemic lupus erythematosus-SLE and 50 healthy subjects) for serum IgG to MOG and AQP4. Furthermore, we investigated whether these antibodies can mediate complement dependent cytotoxicity (CDC). AQP4-IgG was found in patients with NMO (n = 43, 96%), HR-NMO (n = 32, 60%) and in one CIS patient (3%), but was absent in ADEM, MS and controls. High-titer MOG-IgG was found in patients with ADEM (n = 14, 42%), NMO (n = 3, 7%), HR-NMO (n = 7, 13%, 5 rON and 2 LETM), CIS (n = 2, 6%), MS (n = 2, 3%) and controls (n = 3, 3%, two SLE and one OND). Two of the three MOG-IgG positive NMO patients and all seven MOG-IgG positive HR-NMO patients were negative for AQP4-IgG. Thus, MOG-IgG were found in both AQP4-IgG seronegative NMO patients and seven of 21 (33%) AQP4-IgG negative HR-NMO patients. Antibodies to MOG and AQP4 were predominantly of the IgG1 subtype, and were able to mediate CDC at high-titer levels. We could show for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IgG mediated immune response, whereas MOG is not a target antigen in cases with an AQP4-directed humoral immune response.
Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all NMO patients and the target of the autoimmune response in these patients is unknown. Since recent studies indicate that autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) can induce an NMO-like disease in experimental animal models, we speculate that MOG might be an autoantigen in AQP4-IgG seronegative NMO. Although high-titer autoantibodies to human native MOG were mainly detected in a subgroup of pediatric acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) patients, their role in NMO and High-risk NMO (HR-NMO; recurrent optic neuritis-rON or longitudinally extensive transverse myelitis-LETM) remains unresolved. We analyzed patients with definite NMO (n = 45), HR-NMO (n = 53), ADEM (n = 33), clinically isolated syndromes presenting with myelitis or optic neuritis (CIS, n = 32), MS (n = 71) and controls (n = 101; 24 other neurological diseases-OND, 27 systemic lupus erythematosus-SLE and 50 healthy subjects) for serum IgG to MOG and AQP4. Furthermore, we investigated whether these antibodies can mediate complement dependent cytotoxicity (CDC). AQP4-IgG was found in patients with NMO (n = 43, 96%), HR-NMO (n = 32, 60%) and in one CIS patient (3%), but was absent in ADEM, MS and controls. High-titer MOG-IgG was found in patients with ADEM (n = 14, 42%), NMO (n = 3, 7%), HR-NMO (n = 7, 13%, 5 rON and 2 LETM), CIS (n = 2, 6%), MS (n = 2, 3%) and controls (n = 3, 3%, two SLE and one OND). Two of the three MOG-IgG positive NMO patients and all seven MOG-IgG positive HR-NMO patients were negative for AQP4-IgG. Thus, MOG-IgG were found in both AQP4-IgG seronegative NMO patients and seven of 21 (33%) AQP4-IgG negative HR-NMO patients. Antibodies to MOG and AQP4 were predominantly of the IgG1 subtype, and were able to mediate CDC at high-titer levels. We could show for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IgG mediated immune response, whereas MOG is not a target antigen in cases with an AQP4-directed humoral immune response.
Abstract Background: Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all NMO patients and the target of the autoimmune response in these patients is unknown. Since recent studies indicate that autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) can induce an NMO-like disease in experimental animal models, we speculate that MOG might be an autoantigen in AQP4-IgG seronegative NMO. Although high-titer autoantibodies to human native MOG were mainly detected in a subgroup of pediatric acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) patients, their role in NMO and High-risk NMO (HR-NMO; recurrent optic neuritis-rON or longitudinally extensive transverse myelitis-LETM) remains unresolved. Results: We analyzed patients with definite NMO (n = 45), HR-NMO (n = 53), ADEM (n = 33), clinically isolated syndromes presenting with myelitis or optic neuritis (CIS, n = 32), MS (n = 71) and controls (n = 101; 24 other neurological diseases-OND, 27 systemic lupus erythematosus-SLE and 50 healthy subjects) for serum IgG to MOG and AQP4. Furthermore, we investigated whether these antibodies can mediate complement dependent cytotoxicity (CDC). AQP4-IgG was found in patients with NMO (n = 43, 96%), HR-NMO (n = 32, 60%) and in one CIS patient (3%), but was absent in ADEM, MS and controls. High-titer MOG-IgG was found in patients with ADEM (n = 14, 42%), NMO (n = 3, 7%), HR-NMO (n = 7, 13%, 5 rON and 2 LETM), CIS (n = 2, 6%), MS (n = 2, 3%) and controls (n = 3, 3%, two SLE and one OND). Two of the three MOG-IgG positive NMO patients and all seven MOG-IgG positive HR-NMO patients were negative for AQP4-IgG. Thus, MOG-IgG were found in both AQP4-IgG seronegative NMO patients and seven of 21 (33%) AQP4-IgG negative HR-NMO patients. Antibodies to MOG and AQP4 were predominantly of the IgG1 subtype, and were able to mediate CDC at high-titer levels. Conclusions: We could show for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IgG mediated immune response, whereas MOG is not a target antigen in cases with an AQP4-directed humoral immune response.
Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all NMO patients and the target of the autoimmune response in these patients is unknown. Since recent studies indicate that autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) can induce an NMO-like disease in experimental animal models, we speculate that MOG might be an autoantigen in AQP4-IgG seronegative NMO. Although high-titer autoantibodies to human native MOG were mainly detected in a subgroup of pediatric acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) patients, their role in NMO and High-risk NMO (HR-NMO; recurrent optic neuritis-rON or longitudinally extensive transverse myelitis-LETM) remains unresolved.BACKGROUNDSerum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all NMO patients and the target of the autoimmune response in these patients is unknown. Since recent studies indicate that autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) can induce an NMO-like disease in experimental animal models, we speculate that MOG might be an autoantigen in AQP4-IgG seronegative NMO. Although high-titer autoantibodies to human native MOG were mainly detected in a subgroup of pediatric acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) patients, their role in NMO and High-risk NMO (HR-NMO; recurrent optic neuritis-rON or longitudinally extensive transverse myelitis-LETM) remains unresolved.We analyzed patients with definite NMO (n = 45), HR-NMO (n = 53), ADEM (n = 33), clinically isolated syndromes presenting with myelitis or optic neuritis (CIS, n = 32), MS (n = 71) and controls (n = 101; 24 other neurological diseases-OND, 27 systemic lupus erythematosus-SLE and 50 healthy subjects) for serum IgG to MOG and AQP4. Furthermore, we investigated whether these antibodies can mediate complement dependent cytotoxicity (CDC). AQP4-IgG was found in patients with NMO (n = 43, 96%), HR-NMO (n = 32, 60%) and in one CIS patient (3%), but was absent in ADEM, MS and controls. High-titer MOG-IgG was found in patients with ADEM (n = 14, 42%), NMO (n = 3, 7%), HR-NMO (n = 7, 13%, 5 rON and 2 LETM), CIS (n = 2, 6%), MS (n = 2, 3%) and controls (n = 3, 3%, two SLE and one OND). Two of the three MOG-IgG positive NMO patients and all seven MOG-IgG positive HR-NMO patients were negative for AQP4-IgG. Thus, MOG-IgG were found in both AQP4-IgG seronegative NMO patients and seven of 21 (33%) AQP4-IgG negative HR-NMO patients. Antibodies to MOG and AQP4 were predominantly of the IgG1 subtype, and were able to mediate CDC at high-titer levels.RESULTSWe analyzed patients with definite NMO (n = 45), HR-NMO (n = 53), ADEM (n = 33), clinically isolated syndromes presenting with myelitis or optic neuritis (CIS, n = 32), MS (n = 71) and controls (n = 101; 24 other neurological diseases-OND, 27 systemic lupus erythematosus-SLE and 50 healthy subjects) for serum IgG to MOG and AQP4. Furthermore, we investigated whether these antibodies can mediate complement dependent cytotoxicity (CDC). AQP4-IgG was found in patients with NMO (n = 43, 96%), HR-NMO (n = 32, 60%) and in one CIS patient (3%), but was absent in ADEM, MS and controls. High-titer MOG-IgG was found in patients with ADEM (n = 14, 42%), NMO (n = 3, 7%), HR-NMO (n = 7, 13%, 5 rON and 2 LETM), CIS (n = 2, 6%), MS (n = 2, 3%) and controls (n = 3, 3%, two SLE and one OND). Two of the three MOG-IgG positive NMO patients and all seven MOG-IgG positive HR-NMO patients were negative for AQP4-IgG. Thus, MOG-IgG were found in both AQP4-IgG seronegative NMO patients and seven of 21 (33%) AQP4-IgG negative HR-NMO patients. Antibodies to MOG and AQP4 were predominantly of the IgG1 subtype, and were able to mediate CDC at high-titer levels.We could show for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IgG mediated immune response, whereas MOG is not a target antigen in cases with an AQP4-directed humoral immune response.CONCLUSIONSWe could show for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IgG mediated immune response, whereas MOG is not a target antigen in cases with an AQP4-directed humoral immune response.
BACKGROUND: Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all NMO patients and the target of the autoimmune response in these patients is unknown. Since recent studies indicate that autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) can induce an NMO-like disease in experimental animal models, we speculate that MOG might be an autoantigen in AQP4-IgG seronegative NMO. Although high-titer autoantibodies to human native MOG were mainly detected in a subgroup of pediatric acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) patients, their role in NMO and High-risk NMO (HR-NMO; recurrent optic neuritis-rON or longitudinally extensive transverse myelitis-LETM) remains unresolved. RESULTS: We analyzed patients with definite NMO (n = 45), HR-NMO (n = 53), ADEM (n = 33), clinically isolated syndromes presenting with myelitis or optic neuritis (CIS, n = 32), MS (n = 71) and controls (n = 101; 24 other neurological diseases-OND, 27 systemic lupus erythematosus-SLE and 50 healthy subjects) for serum IgG to MOG and AQP4. Furthermore, we investigated whether these antibodies can mediate complement dependent cytotoxicity (CDC). AQP4-IgG was found in patients with NMO (n = 43, 96%), HR-NMO (n = 32, 60%) and in one CIS patient (3%), but was absent in ADEM, MS and controls. High-titer MOG-IgG was found in patients with ADEM (n = 14, 42%), NMO (n = 3, 7%), HR-NMO (n = 7, 13%, 5 rON and 2 LETM), CIS (n = 2, 6%), MS (n = 2, 3%) and controls (n = 3, 3%, two SLE and one OND). Two of the three MOG-IgG positive NMO patients and all seven MOG-IgG positive HR-NMO patients were negative for AQP4-IgG. Thus, MOG-IgG were found in both AQP4-IgG seronegative NMO patients and seven of 21 (33%) AQP4-IgG negative HR-NMO patients. Antibodies to MOG and AQP4 were predominantly of the IgG1 subtype, and were able to mediate CDC at high-titer levels. CONCLUSIONS: We could show for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IgG mediated immune response, whereas MOG is not a target antigen in cases with an AQP4-directed humoral immune response.
ArticleNumber 184
Audience Academic
Author Kristoferitsch, Wolfgang
Rostasy, Kevin
Drulovic, Jelena
Deisenhammer, Florian
Reindl, Markus
Lutterotti, Andreas
Di Pauli, Franziska
Ehling, Rainer
Koson, Peter
Schanda, Kathrin
Berger, Thomas
Jarius, Sven
Kuenz, Bettina
Aboul-Enein, Fahmy
Mader, Simone
Dujmovic, Irena
Gredler, Viktoria
Hegen, Harald
Pfaller, Kristian
Storch, Maria K
AuthorAffiliation 2 Department of Pediatrics IV, Division of Pediatric Neurology and Inborn Errors of Metabolism, Innsbruck Medical University, Innsbruck, Austria
3 Clinic of Neurology, Clinical Center of Serbia, Belgrade, Serbia
7 Department of Neurology, Medical University of Graz, Graz, Austria
6 Department of Neurology, SMZ-Ost Donauspital, Vienna, Austria
9 Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia
1 Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
5 Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany
4 Division of Histology and Embryology, Innsbruck Medical University, Austria
8 Department of Neurology, Slovak Medical University, University Hospital Ruzinov, Bratislava, Slovakia
10 Faculty of Medicine, University of Belgrade, Belgrade, Serbia
11 Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Vienna, Austria
AuthorAffiliation_xml – name: 5 Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany
– name: 6 Department of Neurology, SMZ-Ost Donauspital, Vienna, Austria
– name: 9 Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia
– name: 3 Clinic of Neurology, Clinical Center of Serbia, Belgrade, Serbia
– name: 7 Department of Neurology, Medical University of Graz, Graz, Austria
– name: 2 Department of Pediatrics IV, Division of Pediatric Neurology and Inborn Errors of Metabolism, Innsbruck Medical University, Innsbruck, Austria
– name: 1 Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
– name: 4 Division of Histology and Embryology, Innsbruck Medical University, Austria
– name: 10 Faculty of Medicine, University of Belgrade, Belgrade, Serbia
– name: 8 Department of Neurology, Slovak Medical University, University Hospital Ruzinov, Bratislava, Slovakia
– name: 11 Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Vienna, Austria
Author_xml – sequence: 1
  givenname: Simone
  surname: Mader
  fullname: Mader, Simone
– sequence: 2
  givenname: Viktoria
  surname: Gredler
  fullname: Gredler, Viktoria
– sequence: 3
  givenname: Kathrin
  surname: Schanda
  fullname: Schanda, Kathrin
– sequence: 4
  givenname: Kevin
  surname: Rostasy
  fullname: Rostasy, Kevin
– sequence: 5
  givenname: Irena
  surname: Dujmovic
  fullname: Dujmovic, Irena
– sequence: 6
  givenname: Kristian
  surname: Pfaller
  fullname: Pfaller, Kristian
– sequence: 7
  givenname: Andreas
  surname: Lutterotti
  fullname: Lutterotti, Andreas
– sequence: 8
  givenname: Sven
  surname: Jarius
  fullname: Jarius, Sven
– sequence: 9
  givenname: Franziska
  surname: Di Pauli
  fullname: Di Pauli, Franziska
– sequence: 10
  givenname: Bettina
  surname: Kuenz
  fullname: Kuenz, Bettina
– sequence: 11
  givenname: Rainer
  surname: Ehling
  fullname: Ehling, Rainer
– sequence: 12
  givenname: Harald
  surname: Hegen
  fullname: Hegen, Harald
– sequence: 13
  givenname: Florian
  surname: Deisenhammer
  fullname: Deisenhammer, Florian
– sequence: 14
  givenname: Fahmy
  surname: Aboul-Enein
  fullname: Aboul-Enein, Fahmy
– sequence: 15
  givenname: Maria K
  surname: Storch
  fullname: Storch, Maria K
– sequence: 16
  givenname: Peter
  surname: Koson
  fullname: Koson, Peter
– sequence: 17
  givenname: Jelena
  surname: Drulovic
  fullname: Drulovic, Jelena
– sequence: 18
  givenname: Wolfgang
  surname: Kristoferitsch
  fullname: Kristoferitsch, Wolfgang
– sequence: 19
  givenname: Thomas
  surname: Berger
  fullname: Berger, Thomas
– sequence: 20
  givenname: Markus
  surname: Reindl
  fullname: Reindl, Markus
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22204662$$D View this record in MEDLINE/PubMed
BookMark eNp1kstr3DAQh01JaR7tubdi2kNPTiz5IflSSJc2CQR6ac9ClsauFlmzleTA_veVd5OQDQkSyMz85vO8TrMjhw6y7CMpzwnh7QVhNS1o2dUFLwiv32Qnj5ajJ9_H2WkI67KsaNPSd9kxpbSs25aeZPMKp42FCVzMpYrmTkbjxly6aHrUBkIeMZ-2YI3L0ZoRNTjtUW0j5KPdKtx4jJCc6TqYPe600YQcN9EomUg692BlBJ1rE9Br8OF99naQNsCH-_cs-_Pzx-_VdXH76-pmdXlb9C1jsdAtaNX1nBKodEsapWpFGgp0IGUnOe0ZkLZlQzk0MCitaDdQQgfGGqmVrFR1lt3suRrlWmy8maTfCpRG7AzoRyF9StOC4IwT0DWXrCG1ZFQ2ksmGVrrjqqS9Tqxve9Zm7qeUV-qYl_YAeuhx5q8Y8U5UlPGKNwnwfQ_oDb4COPQonMQyQrGMUHCRBpwgX--z8PhvhhDFZIICa6UDnIPoKGnaknQ8KT8_U65x9i61exGRild0EX3Zi0aZemDcgOnPakGKS8q6Lt0d6vwFVToaJqPSRg4m2Q8CPj3t1WOND3uXBM1eoDyG4GEQysS0erhUbqwgpVj2-4XyL57FPaBfi_gPOiD-yg
CitedBy_id crossref_primary_10_1016_j_msard_2023_104730
crossref_primary_10_1212_NXI_0000000000000257
crossref_primary_10_1093_brain_aws105
crossref_primary_10_1212_NXI_0000000000000134
crossref_primary_10_1016_j_jneuroim_2015_10_007
crossref_primary_10_1016_j_msard_2024_105423
crossref_primary_10_1080_10799893_2020_1830109
crossref_primary_10_1186_s12883_022_02637_x
crossref_primary_10_1007_s00415_020_10024_0
crossref_primary_10_1038_s41582_018_0112_x
crossref_primary_10_3390_children6060075
crossref_primary_10_1007_s00415_017_8615_8
crossref_primary_10_1016_j_jns_2017_05_044
crossref_primary_10_1212_NXI_0000000000000012
crossref_primary_10_36740_WLek202201125
crossref_primary_10_1007_s00415_018_8781_3
crossref_primary_10_1111_bpa_12084
crossref_primary_10_1136_jnnp_2015_311743
crossref_primary_10_1212_WNL_0000000000000101
crossref_primary_10_2147_NDT_S372446
crossref_primary_10_1186_s12974_016_0678_4
crossref_primary_10_1007_s10067_017_3724_4
crossref_primary_10_17116_jnevro20191192218
crossref_primary_10_1016_j_msard_2023_105034
crossref_primary_10_1055_a_1219_7907
crossref_primary_10_1016_S1474_4422_15_00313_0
crossref_primary_10_1111_ene_12679
crossref_primary_10_1177_1756286418762083
crossref_primary_10_1016_j_jns_2018_11_029
crossref_primary_10_1016_j_jns_2024_123041
crossref_primary_10_1371_journal_pone_0214404
crossref_primary_10_1007_s00115_012_3602_x
crossref_primary_10_1016_j_cyto_2015_01_005
crossref_primary_10_1016_j_smim_2025_101944
crossref_primary_10_3389_fneur_2020_00031
crossref_primary_10_1007_s00415_017_8583_z
crossref_primary_10_1212_NXI_0000000000200035
crossref_primary_10_1016_j_jocn_2022_05_002
crossref_primary_10_1007_s00415_020_10026_y
crossref_primary_10_1016_j_xcrm_2022_100913
crossref_primary_10_3389_fneur_2021_679430
crossref_primary_10_1016_j_jns_2020_117289
crossref_primary_10_1016_j_jneuroim_2015_10_002
crossref_primary_10_1111_jnc_14339
crossref_primary_10_1016_j_msard_2023_105150
crossref_primary_10_1016_S1474_4422_12_70133_3
crossref_primary_10_1073_pnas_2300648120
crossref_primary_10_1007_s00415_017_8445_8
crossref_primary_10_1186_s12883_014_0224_x
crossref_primary_10_1016_j_ejpn_2020_11_001
crossref_primary_10_1136_bjophthalmol_2018_313142
crossref_primary_10_1016_j_preteyeres_2013_03_001
crossref_primary_10_1007_s00415_023_11634_0
crossref_primary_10_1038_nrneurol_2012_203
crossref_primary_10_1186_s40478_017_0495_8
crossref_primary_10_3389_fimmu_2019_01189
crossref_primary_10_1016_j_jns_2013_08_034
crossref_primary_10_1111_cen3_12771
crossref_primary_10_2217_nmt_2017_0033
crossref_primary_10_1177_1971400917698856
crossref_primary_10_1016_j_banm_2022_01_032
crossref_primary_10_3389_fneur_2018_00841
crossref_primary_10_3389_fneur_2021_673472
crossref_primary_10_1038_s41467_020_16625_7
crossref_primary_10_1080_01658107_2023_2172434
crossref_primary_10_1007_s00415_021_10619_1
crossref_primary_10_1016_j_jns_2012_06_010
crossref_primary_10_1097_WCO_0b013e3283533a64
crossref_primary_10_17116_jnevro20211210725
crossref_primary_10_1212_NXI_0000000000000702
crossref_primary_10_1007_s11481_013_9487_z
crossref_primary_10_1016_j_msard_2025_106269
crossref_primary_10_1016_j_jns_2015_05_034
crossref_primary_10_1111_nyas_12794
crossref_primary_10_1016_j_jneuroim_2020_577194
crossref_primary_10_1212_NXI_0000000000000141
crossref_primary_10_1016_j_jns_2018_09_005
crossref_primary_10_1177_1756286418761697
crossref_primary_10_1038_s41572_020_0214_9
crossref_primary_10_4103_NRR_NRR_D_24_00109
crossref_primary_10_1002_acn3_52191
crossref_primary_10_1053_j_sult_2023_03_017
crossref_primary_10_1177_1352458514551457
crossref_primary_10_1111_cei_12271
crossref_primary_10_1212_NXI_0000000000200059
crossref_primary_10_1177_1352458514551455
crossref_primary_10_1055_a_1918_1824
crossref_primary_10_1177_1352458514551454
crossref_primary_10_1212_NXI_0000000000000731
crossref_primary_10_3389_fimmu_2017_00529
crossref_primary_10_1016_j_jneuroim_2017_01_007
crossref_primary_10_1016_j_msard_2021_103044
crossref_primary_10_1016_j_neuarg_2014_03_003
crossref_primary_10_23838_pfm_2021_00198
crossref_primary_10_1186_s40478_020_00920_x
crossref_primary_10_2217_frd_2021_0011
crossref_primary_10_1016_j_msard_2017_02_003
crossref_primary_10_1136_jnnp_2017_315998
crossref_primary_10_4103_aian_aian_860_21
crossref_primary_10_1177_1352458516669002
crossref_primary_10_1007_s00281_014_0424_x
crossref_primary_10_1177_1352458515622986
crossref_primary_10_1186_s12974_016_0717_1
crossref_primary_10_1212_NXI_0000000000000175
crossref_primary_10_1016_j_cca_2012_04_027
crossref_primary_10_1371_journal_pone_0149411
crossref_primary_10_1007_s00401_020_02236_5
crossref_primary_10_1371_journal_pone_0079188
crossref_primary_10_1016_j_braindev_2014_02_002
crossref_primary_10_1016_j_jneuroim_2014_03_001
crossref_primary_10_1007_s12264_019_00375_8
crossref_primary_10_1038_nrneurol_2013_118
crossref_primary_10_1111_ene_12759
crossref_primary_10_1111_dmcn_14594
crossref_primary_10_1016_j_msard_2018_10_013
crossref_primary_10_1212_NXI_0000000000000040
crossref_primary_10_3109_01658107_2015_1084332
crossref_primary_10_1093_rheumatology_key282
crossref_primary_10_1007_s00115_018_0607_0
crossref_primary_10_1186_s12974_016_0719_z
crossref_primary_10_3389_fimmu_2015_00517
crossref_primary_10_1016_j_braindev_2018_10_011
crossref_primary_10_1172_jci_insight_165373
crossref_primary_10_1186_s12974_018_1144_2
crossref_primary_10_3389_fimmu_2017_00652
crossref_primary_10_1016_j_jns_2020_117002
crossref_primary_10_1038_nrneurol_2014_141
crossref_primary_10_1016_j_jneuroim_2022_577858
crossref_primary_10_1097_WNO_0000000000000689
crossref_primary_10_1177_1352458517699791
crossref_primary_10_1186_s12974_019_1525_1
crossref_primary_10_1016_j_lpm_2014_05_030
crossref_primary_10_1016_S1474_4422_12_70301_0
crossref_primary_10_1007_s10384_021_00840_w
crossref_primary_10_3345_cep_2019_01305
crossref_primary_10_3389_fneur_2019_01070
crossref_primary_10_1177_2055217317743098
crossref_primary_10_1007_s00415_017_8635_4
crossref_primary_10_3390_app13085029
crossref_primary_10_1002_ana_25291
crossref_primary_10_1016_j_msard_2024_105926
crossref_primary_10_1016_j_msard_2012_06_003
crossref_primary_10_3389_fneur_2018_00648
crossref_primary_10_1016_j_msard_2020_102376
crossref_primary_10_1007_s00115_021_01106_z
crossref_primary_10_3389_fneur_2023_1209749
crossref_primary_10_1016_j_msard_2020_102251
crossref_primary_10_1097_WNO_0000000000000779
crossref_primary_10_1212_WNL_0000000000002821
crossref_primary_10_1590_0004_282X20140032
crossref_primary_10_1016_j_jns_2015_08_022
crossref_primary_10_1111_ene_12898
crossref_primary_10_1007_s00401_020_02132_y
crossref_primary_10_1016_j_jneuroim_2021_577693
crossref_primary_10_1016_j_ab_2022_114721
crossref_primary_10_1186_s12974_017_0929_z
crossref_primary_10_1212_NXI_0000000000000062
crossref_primary_10_3109_08916934_2014_883501
crossref_primary_10_1148_rg_2020200032
crossref_primary_10_1186_s12974_016_0720_6
crossref_primary_10_3389_fimmu_2021_686466
crossref_primary_10_1016_j_neurol_2018_01_378
crossref_primary_10_1177_13524585251317339
crossref_primary_10_1177_20552173221128170
crossref_primary_10_1212_WNL_0b013e31826aadaf
crossref_primary_10_1016_j_msard_2020_102005
crossref_primary_10_4103_aian_aian_406_21
crossref_primary_10_1212_WNL_0b013e318296e917
crossref_primary_10_1186_s12883_022_02974_x
crossref_primary_10_4049_jimmunol_1801295
crossref_primary_10_1186_s40893_016_0008_9
crossref_primary_10_1212_WNL_0000000000004312
crossref_primary_10_1111_dmcn_14336
crossref_primary_10_1007_s00296_014_3066_3
crossref_primary_10_1097_WNO_0000000000000669
crossref_primary_10_1097_APO_0000000000000513
crossref_primary_10_1007_s00401_016_1559_8
crossref_primary_10_1038_s41582_024_01014_1
crossref_primary_10_1016_j_jneuroim_2023_578198
crossref_primary_10_3389_fneur_2020_00415
crossref_primary_10_1007_s11940_012_0170_0
crossref_primary_10_1016_j_yapd_2019_03_003
crossref_primary_10_1186_s12974_020_01825_1
crossref_primary_10_1016_j_jneuroim_2020_577260
crossref_primary_10_1111_ceo_13863
crossref_primary_10_1177_1352458514566666
crossref_primary_10_1016_j_msard_2018_11_007
crossref_primary_10_1016_j_msard_2018_03_003
crossref_primary_10_1007_s10072_023_07050_x
crossref_primary_10_1016_j_jns_2017_08_3254
crossref_primary_10_1093_braincomms_fcae106
crossref_primary_10_1016_j_msard_2018_07_026
crossref_primary_10_1016_j_msard_2018_07_025
crossref_primary_10_1186_s12974_015_0256_1
crossref_primary_10_28982_josam_955602
crossref_primary_10_1007_s00415_019_09498_4
crossref_primary_10_1111_cen3_12491
crossref_primary_10_1016_S1773_035X_16_30241_6
crossref_primary_10_3390_biomedicines7020042
crossref_primary_10_3389_fimmu_2022_900605
crossref_primary_10_3389_fnins_2023_1014071
crossref_primary_10_1007_s00415_013_7210_x
crossref_primary_10_1186_s12974_022_02420_2
crossref_primary_10_3390_ijms160716576
crossref_primary_10_1038_s41573_020_00092_2
crossref_primary_10_1136_jnnp_2018_317969
crossref_primary_10_1212_NXI_0000000000000089
crossref_primary_10_1186_s12974_018_1108_6
crossref_primary_10_1126_scitranslmed_abe9726
crossref_primary_10_1097_ICU_0b013e3283641b86
crossref_primary_10_1136_jnnp_2014_308346
crossref_primary_10_1007_s00415_022_11482_4
crossref_primary_10_1097_ICU_0000000000000520
crossref_primary_10_1016_j_msard_2024_106222
crossref_primary_10_1097_WCO_0000000000000331
crossref_primary_10_1212_CON_0000000000001127
crossref_primary_10_1080_1744666X_2022_2105205
crossref_primary_10_3390_biomedicines8050130
crossref_primary_10_3390_children7110210
crossref_primary_10_1007_s10072_013_1481_y
crossref_primary_10_1146_annurev_immunol_020711_075041
crossref_primary_10_1016_j_msard_2017_09_019
crossref_primary_10_1016_j_msard_2021_103020
crossref_primary_10_1002_art_40356
crossref_primary_10_1097_WCO_0000000000000328
crossref_primary_10_1212_NXI_0000000000000674
crossref_primary_10_1016_j_neuint_2018_10_016
crossref_primary_10_1136_jnnp_2020_324422
crossref_primary_10_1016_j_jns_2012_12_014
crossref_primary_10_1111_cen3_12262
crossref_primary_10_1111_ane_13054
crossref_primary_10_4049_jimmunol_2300015
crossref_primary_10_1002_brb3_1338
crossref_primary_10_17116_jnevro202012007297
crossref_primary_10_1016_j_msard_2023_105406
crossref_primary_10_1186_s12974_016_0718_0
crossref_primary_10_1007_s42451_018_0051_1
crossref_primary_10_1177_1352458514555785
crossref_primary_10_1177_1352458519887905
crossref_primary_10_1371_journal_pone_0079083
crossref_primary_10_1002_ana_25927
crossref_primary_10_29252_nirp_cjns_3_11_231
crossref_primary_10_1097_WCO_0000000000000443
crossref_primary_10_1177_1352458515613165
crossref_primary_10_1177_1756286420945135
crossref_primary_10_4049_jimmunol_1301296
crossref_primary_10_1136_bcr_2022_249915
crossref_primary_10_1073_pnas_1519608113
crossref_primary_10_1177_1352458512470310
crossref_primary_10_3389_fneur_2020_00089
crossref_primary_10_1016_j_msard_2021_103260
crossref_primary_10_1097_WCO_0000000000000446
crossref_primary_10_1212_NXI_0000000000000543
crossref_primary_10_1016_j_msard_2021_103030
crossref_primary_10_1111_cei_13641
crossref_primary_10_1016_j_autrev_2013_10_003
crossref_primary_10_1186_1742_2094_10_8
crossref_primary_10_1186_2051_5960_2_35
crossref_primary_10_1080_00207454_2016_1259226
crossref_primary_10_3389_fneur_2018_00217
crossref_primary_10_1212_WNL_0000000000000830
crossref_primary_10_1111_nan_12574
crossref_primary_10_1111_aos_14013
crossref_primary_10_1212_NXI_0000000000200337
crossref_primary_10_3389_fneur_2023_1200961
crossref_primary_10_2147_IMCRJ_S459799
crossref_primary_10_1212_NXI_0000000000000456
crossref_primary_10_1007_s11427_015_4997_y
crossref_primary_10_1016_j_pediatrneurol_2019_06_017
crossref_primary_10_1016_j_msard_2025_106313
crossref_primary_10_1177_20552173211063126
crossref_primary_10_3389_fneur_2020_612304
crossref_primary_10_1016_j_jns_2019_07_014
crossref_primary_10_1177_1352458512466317
crossref_primary_10_1212_NXI_0000000000200066
crossref_primary_10_1007_s00330_019_06506_z
crossref_primary_10_1177_2055217318787829
crossref_primary_10_1093_brain_awx276
crossref_primary_10_3389_fimmu_2018_02753
crossref_primary_10_1038_s41598_020_80535_3
crossref_primary_10_1016_j_jneuroim_2018_05_014
crossref_primary_10_1016_j_jneuroim_2021_577742
crossref_primary_10_1016_j_msard_2013_12_001
crossref_primary_10_1093_brain_awab105
crossref_primary_10_1016_j_jns_2013_02_024
crossref_primary_10_1111_cen3_12434
crossref_primary_10_5692_clinicalneurol_cn_001868
crossref_primary_10_1097_WCO_0000000000000813
crossref_primary_10_1002_acn3_164
crossref_primary_10_1097_WCO_0000000000000819
crossref_primary_10_1517_14728222_2012_677438
crossref_primary_10_1212_NXI_0000000000000689
crossref_primary_10_1007_s00401_013_1128_3
crossref_primary_10_1007_s11940_021_00672_6
crossref_primary_10_1007_s00415_015_7694_7
crossref_primary_10_1136_practneurol_2017_001787
crossref_primary_10_1038_s41582_020_0381_z
crossref_primary_10_1177_1352458517734070
crossref_primary_10_3389_fimmu_2021_759389
crossref_primary_10_1177_0961203320978514
crossref_primary_10_1002_glia_24675
crossref_primary_10_1155_2018_5381239
crossref_primary_10_1016_j_ejpn_2020_04_002
crossref_primary_10_1177_1352458516631038
crossref_primary_10_1016_j_ajo_2020_07_008
crossref_primary_10_3389_fneur_2022_912050
crossref_primary_10_1212_WNL_0b013e31826aac4e
crossref_primary_10_1016_j_jns_2020_116673
crossref_primary_10_1111_cen3_12569
crossref_primary_10_1186_s12974_019_1521_5
crossref_primary_10_3389_fneur_2021_660741
crossref_primary_10_1177_1352458515587751
crossref_primary_10_1007_s10072_020_04828_1
crossref_primary_10_1016_j_msard_2021_103463
crossref_primary_10_1186_s12974_017_0984_5
crossref_primary_10_1186_s12974_015_0356_y
crossref_primary_10_1007_s00415_013_7169_7
crossref_primary_10_1186_s12974_020_01824_2
crossref_primary_10_1007_s00415_016_8360_4
crossref_primary_10_1186_s12974_021_02249_1
crossref_primary_10_1007_s13311_015_0400_8
crossref_primary_10_1177_13524585221081090
crossref_primary_10_1186_s12974_021_02138_7
crossref_primary_10_1007_s00062_013_0267_1
crossref_primary_10_1016_j_clineuro_2023_107850
crossref_primary_10_3389_fimmu_2021_679770
crossref_primary_10_1093_jalm_jfab101
crossref_primary_10_1186_s12974_019_1594_1
crossref_primary_10_3389_fneur_2020_00960
crossref_primary_10_1002_ana_24117
crossref_primary_10_1016_j_autrev_2015_12_004
crossref_primary_10_1111_cen3_12578
crossref_primary_10_1097_WNF_0000000000000176
crossref_primary_10_1177_0883073817724927
crossref_primary_10_1016_j_msard_2022_104068
crossref_primary_10_1038_s41583_019_0233_2
crossref_primary_10_1177_1352458515593406
crossref_primary_10_1177_20552173211022767
crossref_primary_10_1186_s12967_024_05801_8
crossref_primary_10_3390_cells8020090
crossref_primary_10_1016_j_msard_2021_103356
crossref_primary_10_3390_ijms17030273
crossref_primary_10_1002_cti2_1316
crossref_primary_10_1016_j_it_2015_09_008
crossref_primary_10_1016_S1773_035X_24_00174_6
crossref_primary_10_1186_s12974_016_0737_x
crossref_primary_10_1016_j_jns_2012_05_018
crossref_primary_10_1016_j_mric_2023_12_001
crossref_primary_10_1093_brain_awaa102
crossref_primary_10_1177_13524585221134214
crossref_primary_10_1111_bpa_12098
crossref_primary_10_1007_s12264_015_1552_6
Cites_doi 10.1093/brain/awp309
10.1074/jbc.M111.227298
10.1002/ana.21916
10.1016/S0304-3940(01)01949-8
10.1212/01.WNL.0000289761.64862.ce
10.1212/01.wnl.0000216139.44259.74
10.1038/nm1488
10.1016/j.clim.2010.11.013
10.1002/jcla.1860090312
10.1620/tjem.210.307
10.1111/j.1750-3639.1998.tb00194.x
10.1016/j.jns.2011.03.028
10.1212/01.wnl.0000303817.82134.da
10.1111/j.1471-4159.1989.tb10930.x
10.1001/archneurol.2007.17
10.1212/01.wnl.0000259422.44235.a8
10.1016/S0161-5890(97)00005-9
10.1016/j.jneuroim.2011.01.007
10.1001/archneurol.2009.188
10.1002/glia.1111
10.1002/glia.20855
10.1111/j.1440-1789.2007.00774.x
10.1093/brain/awh260
10.1055/s-2007-1004521
10.1093/brain/awm062
10.1016/j.jns.2010.07.011
10.1177/1352458510389220
10.1097/WNR.0b013e32832776f4
10.1186/1742-2094-7-50
10.1084/jem.20050304
10.1002/ana.21837
10.1172/JCI28334
10.1212/WNL.0b013e3181dc1a7f
10.1172/JCI28330
10.1016/S0140-6736(04)17551-X
10.1371/journal.pone.0010455
10.1002/ana.20703
10.1021/bi990941s
10.1016/j.bbrc.2009.06.085
10.1001/archneur.65.7.913
10.4049/jimmunol.0801888
10.1212/WNL.0b013e318228c0b1
10.1002/ana.21802
10.1073/pnas.2235843100
10.1515/CCLM.2010.127
10.1016/S1076-6332(03)80768-7
10.1002/ana.20770
ContentType Journal Article
Copyright COPYRIGHT 2011 BioMed Central Ltd.
2011 Mader et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2011 Mader et al; licensee BioMed Central Ltd. 2011 Mader et al; licensee BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2011 BioMed Central Ltd.
– notice: 2011 Mader et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2011 Mader et al; licensee BioMed Central Ltd. 2011 Mader et al; licensee BioMed Central Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/1742-2094-8-184
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Neurosciences Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Proquest Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1742-2094
EndPage 184
ExternalDocumentID oai_doaj_org_article_8781ed48a7514a72a5a7a523d98c02bd
PMC3278385
oai_biomedcentral_com_1742_2094_8_184
2584457281
A279979998
22204662
10_1186_1742_2094_8_184
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Austria
GeographicLocations_xml – name: Austria
GroupedDBID ---
0R~
29L
2VQ
2WC
4.4
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
INR
IPNFZ
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RIG
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7T5
7TK
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
-A0
ABVAZ
ACRMQ
ADINQ
AFGXO
AFNRJ
C24
5PM
PUEGO
ID FETCH-LOGICAL-b677t-d6edc9b821e3d615cc4c152e2f109a82b7e1667f0f5efcdc29f212f775adca3c3
IEDL.DBID RBZ
ISSN 1742-2094
IngestDate Wed Aug 27 01:30:23 EDT 2025
Thu Aug 21 17:48:19 EDT 2025
Wed May 22 07:16:03 EDT 2024
Fri Jul 11 05:24:38 EDT 2025
Fri Jul 25 04:39:37 EDT 2025
Tue Jun 17 21:17:39 EDT 2025
Tue Jun 10 20:49:12 EDT 2025
Thu Apr 03 07:08:49 EDT 2025
Tue Jul 01 02:54:21 EDT 2025
Thu Apr 24 23:04:24 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b677t-d6edc9b821e3d615cc4c152e2f109a82b7e1667f0f5efcdc29f212f775adca3c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://dx.doi.org/10.1186/1742-2094-8-184
PMID 22204662
PQID 921138328
PQPubID 55345
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_8781ed48a7514a72a5a7a523d98c02bd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3278385
biomedcentral_primary_oai_biomedcentral_com_1742_2094_8_184
proquest_miscellaneous_921560198
proquest_journals_921138328
gale_infotracmisc_A279979998
gale_infotracacademiconefile_A279979998
pubmed_primary_22204662
crossref_citationtrail_10_1186_1742_2094_8_184
crossref_primary_10_1186_1742_2094_8_184
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-12-28
PublicationDateYYYYMMDD 2011-12-28
PublicationDate_xml – month: 12
  year: 2011
  text: 2011-12-28
  day: 28
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of neuroinflammation
PublicationTitleAlternate J Neuroinflammation
PublicationYear 2011
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References VA Lennon (497_CR1) 2005; 202
SR Hinson (497_CR42) 2009; 66
S Saadoun (497_CR34) 2010; 133
S Mader (497_CR9) 2010; 5
M Kinoshita (497_CR41) 2009; 20
GP Nicchia (497_CR7) 2009; 57
J Satoh (497_CR4) 2007; 27
N Ishikawa (497_CR40) 2007; 38
SR Hinson (497_CR32) 2007; 69
A Iglesias (497_CR22) 2001; 36
MJ Fritzler (497_CR45) 1995; 9
M Matiello (497_CR11) 2008; 70
F Di Pauli (497_CR24) 2011; 138
E Bettelli (497_CR19) 2006; 116
PH Lalive (497_CR29) 2011; 17
DM Wingerchuk (497_CR3) 2006; 66
I Dujmovic (497_CR48) 2011; 234
SJ Pittock (497_CR10) 2008; 65
JM Crane (497_CR8) 2011; 286
S Jarius (497_CR16) 2010; 48
LB Krupp (497_CR46) 2007; 68
JW Haller (497_CR49) 2001; 8
BG Weinshenker (497_CR13) 2006; 59
G Krishnamoorthy (497_CR20) 2006; 116
KH Chan (497_CR44) 2010; 7
JD Neely (497_CR5) 1999; 38
VA Lennon (497_CR2) 2004; 364
S Jarius (497_CR38) 2011
S Jarius (497_CR12) 2010; 298
M Bradl (497_CR33) 2009; 66
AK Probstel (497_CR37) 2011
CG Haase (497_CR30) 2001; 307
T Takahashi (497_CR14) 2007; 130
P Waters (497_CR15) 2008; 65
J Palace (497_CR17) 2011; 306
KA McLaughlin (497_CR27) 2009; 183
T Takahashi (497_CR43) 2006; 210
C Brunner (497_CR18) 1989; 52
MK Storch (497_CR21) 1998; 8
TG Johns (497_CR31) 1997; 34
M Kinoshita (497_CR35) 2009; 386
MC Kruer (497_CR39) 2010; 74
AK Probstel (497_CR28) 2011; 77
F Brilot (497_CR26) 2009; 66
JL Bennett (497_CR36) 2009; 66
CS Furman (497_CR6) 2003; 100
H Sakuma (497_CR23) 2004; 127
KC O'Connor (497_CR25) 2007; 13
CH Polman (497_CR47) 2005; 58
16955141 - J Clin Invest. 2006 Sep;116(9):2393-402
17146196 - Tohoku J Exp Med. 2006 Dec;210(4):307-13
16955140 - J Clin Invest. 2006 Sep;116(9):2385-92
20822515 - J Neuroinflammation. 2010;7:50
21316112 - J Neuroimmunol. 2011 May;234(1-2):124-30
21169067 - Clin Immunol. 2011 Mar;138(3):247-54
22138095 - Clin Neurol Neurosurg. 2012 May;114(4):331-5
15589308 - Lancet. 2004 Dec 11-17;364(9451):2106-12
17438241 - Neurology. 2007 Apr 17;68(16 Suppl 2):S7-12
17645239 - Neuropathology. 2007 Jun;27(3):245-56
20184532 - Clin Chem Lab Med. 2010 May;48(5):659-63
17928579 - Neurology. 2007 Dec 11;69(24):2221-31
11596130 - Glia. 2001 Nov;36(2):220-34
14597700 - Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13609-14
16283615 - Ann Neurol. 2005 Dec;58(6):840-6
11427318 - Neurosci Lett. 2001 Jul 13;307(2):131-3
11724044 - Acad Radiol. 2001 Sep;8(9):888-97
19752309 - Arch Neurol. 2009 Sep;66(9):1164-7
20033986 - Ann Neurol. 2009 Dec;66(6):833-42
9804377 - Brain Pathol. 1998 Oct;8(4):681-94
18330842 - Neuropediatrics. 2007 Oct;38(5):257-60
18625857 - Arch Neurol. 2008 Jul;65(7):913-9
20439851 - Neurology. 2010 May 4;74(18):1473-5
10460172 - Biochemistry. 1999 Aug 24;38(34):11156-63
17449477 - Brain. 2007 May;130(Pt 5):1235-43
15282218 - Brain. 2004 Oct;127(Pt 10):2201-13
7602431 - J Clin Lab Anal. 1995;9(3):218-24
19297740 - Neuroreport. 2009 Mar 25;20(5):508-12
18434643 - Neurology. 2008 Jun 3;70(23):2197-200
21664525 - J Neurol Sci. 2011 Jul 15;306(1-2):188-91
9182874 - Mol Immunol. 1997 Jan;34(1):33-8
20850793 - J Neurol Sci. 2010 Nov 15;298(1-2):158-62
21795651 - Neurology. 2011 Aug 9;77(6):580-8
16717206 - Neurology. 2006 May 23;66(10):1485-9
20047900 - Brain. 2010 Feb;133(Pt 2):349-61
19938104 - Ann Neurol. 2009 Nov;66(5):617-29
2462020 - J Neurochem. 1989 Jan;52(1):296-304
17237795 - Nat Med. 2007 Feb;13(2):211-7
19545538 - Biochem Biophys Res Commun. 2009 Sep 4;386(4):623-7
16453327 - Ann Neurol. 2006 Mar;59(3):566-9
18195142 - Arch Neurol. 2008 Jan;65(1):78-83
16087714 - J Exp Med. 2005 Aug 15;202(4):473-7
19937948 - Ann Neurol. 2009 Nov;66(5):630-43
20463974 - PLoS One. 2010;5(5):e10455
21177754 - Mult Scler. 2011 Mar;17(3):297-302
19687098 - J Immunol. 2009 Sep 15;183(6):4067-76
21454592 - J Biol Chem. 2011 May 6;286(18):16516-24
19229993 - Glia. 2009 Oct;57(13):1363-73
References_xml – volume: 133
  start-page: 349
  issue: Pt 2
  year: 2010
  ident: 497_CR34
  publication-title: Brain
  doi: 10.1093/brain/awp309
– volume: 286
  start-page: 16516
  issue: 18
  year: 2011
  ident: 497_CR8
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M111.227298
– volume: 66
  start-page: 833
  issue: 6
  year: 2009
  ident: 497_CR26
  publication-title: Annals of neurology
  doi: 10.1002/ana.21916
– volume-title: Neurology
  year: 2011
  ident: 497_CR37
– volume: 307
  start-page: 131
  issue: 2
  year: 2001
  ident: 497_CR30
  publication-title: Neurosci Lett
  doi: 10.1016/S0304-3940(01)01949-8
– volume: 69
  start-page: 2221
  issue: 24
  year: 2007
  ident: 497_CR32
  publication-title: Neurology
  doi: 10.1212/01.WNL.0000289761.64862.ce
– volume: 66
  start-page: 1485
  issue: 10
  year: 2006
  ident: 497_CR3
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000216139.44259.74
– volume: 13
  start-page: 211
  issue: 2
  year: 2007
  ident: 497_CR25
  publication-title: Nat Med
  doi: 10.1038/nm1488
– volume: 138
  start-page: 247
  issue: 3
  year: 2011
  ident: 497_CR24
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2010.11.013
– volume: 9
  start-page: 218
  issue: 3
  year: 1995
  ident: 497_CR45
  publication-title: J Clin Lab Anal
  doi: 10.1002/jcla.1860090312
– volume: 210
  start-page: 307
  issue: 4
  year: 2006
  ident: 497_CR43
  publication-title: Tohoku J Exp Med
  doi: 10.1620/tjem.210.307
– volume: 8
  start-page: 681
  issue: 4
  year: 1998
  ident: 497_CR21
  publication-title: Brain Pathol
  doi: 10.1111/j.1750-3639.1998.tb00194.x
– volume: 306
  start-page: 188
  issue: 1-2
  year: 2011
  ident: 497_CR17
  publication-title: J Neurol Sci
  doi: 10.1016/j.jns.2011.03.028
– volume: 70
  start-page: 2197
  issue: 23
  year: 2008
  ident: 497_CR11
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000303817.82134.da
– volume: 52
  start-page: 296
  issue: 1
  year: 1989
  ident: 497_CR18
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.1989.tb10930.x
– volume: 65
  start-page: 78
  issue: 1
  year: 2008
  ident: 497_CR10
  publication-title: Arch Neurol
  doi: 10.1001/archneurol.2007.17
– volume: 68
  start-page: S7
  issue: 16 Suppl 2
  year: 2007
  ident: 497_CR46
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000259422.44235.a8
– volume: 34
  start-page: 33
  issue: 1
  year: 1997
  ident: 497_CR31
  publication-title: Mol Immunol
  doi: 10.1016/S0161-5890(97)00005-9
– volume: 234
  start-page: 124
  issue: 1-2
  year: 2011
  ident: 497_CR48
  publication-title: J Neuroimmunol
  doi: 10.1016/j.jneuroim.2011.01.007
– volume: 66
  start-page: 1164
  issue: 9
  year: 2009
  ident: 497_CR42
  publication-title: Arch Neurol
  doi: 10.1001/archneurol.2009.188
– volume: 36
  start-page: 220
  issue: 2
  year: 2001
  ident: 497_CR22
  publication-title: Glia
  doi: 10.1002/glia.1111
– volume: 57
  start-page: 1363
  issue: 13
  year: 2009
  ident: 497_CR7
  publication-title: Glia
  doi: 10.1002/glia.20855
– volume: 27
  start-page: 245
  issue: 3
  year: 2007
  ident: 497_CR4
  publication-title: Neuropathology
  doi: 10.1111/j.1440-1789.2007.00774.x
– volume-title: Clin Neurol Neurosurg
  year: 2011
  ident: 497_CR38
– volume: 127
  start-page: 2201
  issue: Pt 10
  year: 2004
  ident: 497_CR23
  publication-title: Brain
  doi: 10.1093/brain/awh260
– volume: 38
  start-page: 257
  issue: 5
  year: 2007
  ident: 497_CR40
  publication-title: Neuropediatrics
  doi: 10.1055/s-2007-1004521
– volume: 130
  start-page: 1235
  issue: Pt 5
  year: 2007
  ident: 497_CR14
  publication-title: Brain
  doi: 10.1093/brain/awm062
– volume: 298
  start-page: 158
  issue: 1-2
  year: 2010
  ident: 497_CR12
  publication-title: J Neurol Sci
  doi: 10.1016/j.jns.2010.07.011
– volume: 17
  start-page: 297
  issue: 3
  year: 2011
  ident: 497_CR29
  publication-title: Mult Scler
  doi: 10.1177/1352458510389220
– volume: 20
  start-page: 508
  issue: 5
  year: 2009
  ident: 497_CR41
  publication-title: Neuroreport
  doi: 10.1097/WNR.0b013e32832776f4
– volume: 7
  start-page: 50
  year: 2010
  ident: 497_CR44
  publication-title: J Neuroinflammation
  doi: 10.1186/1742-2094-7-50
– volume: 202
  start-page: 473
  issue: 4
  year: 2005
  ident: 497_CR1
  publication-title: J Exp Med
  doi: 10.1084/jem.20050304
– volume: 66
  start-page: 630
  issue: 5
  year: 2009
  ident: 497_CR33
  publication-title: Ann Neurol
  doi: 10.1002/ana.21837
– volume: 116
  start-page: 2393
  issue: 9
  year: 2006
  ident: 497_CR19
  publication-title: J Clin Invest
  doi: 10.1172/JCI28334
– volume: 74
  start-page: 1473
  issue: 18
  year: 2010
  ident: 497_CR39
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e3181dc1a7f
– volume: 116
  start-page: 2385
  issue: 9
  year: 2006
  ident: 497_CR20
  publication-title: J Clin Invest
  doi: 10.1172/JCI28330
– volume: 364
  start-page: 2106
  issue: 9451
  year: 2004
  ident: 497_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(04)17551-X
– volume: 5
  start-page: e10455
  issue: 5
  year: 2010
  ident: 497_CR9
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0010455
– volume: 58
  start-page: 840
  issue: 6
  year: 2005
  ident: 497_CR47
  publication-title: Annals of neurology
  doi: 10.1002/ana.20703
– volume: 38
  start-page: 11156
  issue: 34
  year: 1999
  ident: 497_CR5
  publication-title: Biochemistry
  doi: 10.1021/bi990941s
– volume: 386
  start-page: 623
  issue: 4
  year: 2009
  ident: 497_CR35
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2009.06.085
– volume: 65
  start-page: 913
  issue: 7
  year: 2008
  ident: 497_CR15
  publication-title: Arch Neurol
  doi: 10.1001/archneur.65.7.913
– volume: 183
  start-page: 4067
  issue: 6
  year: 2009
  ident: 497_CR27
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0801888
– volume: 77
  start-page: 580
  issue: 6
  year: 2011
  ident: 497_CR28
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e318228c0b1
– volume: 66
  start-page: 617
  issue: 5
  year: 2009
  ident: 497_CR36
  publication-title: Ann Neurol
  doi: 10.1002/ana.21802
– volume: 100
  start-page: 13609
  issue: 23
  year: 2003
  ident: 497_CR6
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.2235843100
– volume: 48
  start-page: 659
  issue: 5
  year: 2010
  ident: 497_CR16
  publication-title: Clin Chem Lab Med
  doi: 10.1515/CCLM.2010.127
– volume: 8
  start-page: 888
  issue: 9
  year: 2001
  ident: 497_CR49
  publication-title: Acad Radiol
  doi: 10.1016/S1076-6332(03)80768-7
– volume: 59
  start-page: 566
  issue: 3
  year: 2006
  ident: 497_CR13
  publication-title: Annals of neurology
  doi: 10.1002/ana.20770
– reference: 16087714 - J Exp Med. 2005 Aug 15;202(4):473-7
– reference: 11427318 - Neurosci Lett. 2001 Jul 13;307(2):131-3
– reference: 17928579 - Neurology. 2007 Dec 11;69(24):2221-31
– reference: 7602431 - J Clin Lab Anal. 1995;9(3):218-24
– reference: 20033986 - Ann Neurol. 2009 Dec;66(6):833-42
– reference: 9182874 - Mol Immunol. 1997 Jan;34(1):33-8
– reference: 17449477 - Brain. 2007 May;130(Pt 5):1235-43
– reference: 18330842 - Neuropediatrics. 2007 Oct;38(5):257-60
– reference: 9804377 - Brain Pathol. 1998 Oct;8(4):681-94
– reference: 17146196 - Tohoku J Exp Med. 2006 Dec;210(4):307-13
– reference: 19545538 - Biochem Biophys Res Commun. 2009 Sep 4;386(4):623-7
– reference: 16283615 - Ann Neurol. 2005 Dec;58(6):840-6
– reference: 19687098 - J Immunol. 2009 Sep 15;183(6):4067-76
– reference: 16453327 - Ann Neurol. 2006 Mar;59(3):566-9
– reference: 11596130 - Glia. 2001 Nov;36(2):220-34
– reference: 19752309 - Arch Neurol. 2009 Sep;66(9):1164-7
– reference: 15282218 - Brain. 2004 Oct;127(Pt 10):2201-13
– reference: 19937948 - Ann Neurol. 2009 Nov;66(5):630-43
– reference: 16955141 - J Clin Invest. 2006 Sep;116(9):2393-402
– reference: 10460172 - Biochemistry. 1999 Aug 24;38(34):11156-63
– reference: 17237795 - Nat Med. 2007 Feb;13(2):211-7
– reference: 20184532 - Clin Chem Lab Med. 2010 May;48(5):659-63
– reference: 16955140 - J Clin Invest. 2006 Sep;116(9):2385-92
– reference: 19938104 - Ann Neurol. 2009 Nov;66(5):617-29
– reference: 21795651 - Neurology. 2011 Aug 9;77(6):580-8
– reference: 14597700 - Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13609-14
– reference: 18434643 - Neurology. 2008 Jun 3;70(23):2197-200
– reference: 19297740 - Neuroreport. 2009 Mar 25;20(5):508-12
– reference: 21177754 - Mult Scler. 2011 Mar;17(3):297-302
– reference: 22138095 - Clin Neurol Neurosurg. 2012 May;114(4):331-5
– reference: 18625857 - Arch Neurol. 2008 Jul;65(7):913-9
– reference: 21664525 - J Neurol Sci. 2011 Jul 15;306(1-2):188-91
– reference: 20463974 - PLoS One. 2010;5(5):e10455
– reference: 20850793 - J Neurol Sci. 2010 Nov 15;298(1-2):158-62
– reference: 21454592 - J Biol Chem. 2011 May 6;286(18):16516-24
– reference: 2462020 - J Neurochem. 1989 Jan;52(1):296-304
– reference: 16717206 - Neurology. 2006 May 23;66(10):1485-9
– reference: 20822515 - J Neuroinflammation. 2010;7:50
– reference: 19229993 - Glia. 2009 Oct;57(13):1363-73
– reference: 18195142 - Arch Neurol. 2008 Jan;65(1):78-83
– reference: 20439851 - Neurology. 2010 May 4;74(18):1473-5
– reference: 21316112 - J Neuroimmunol. 2011 May;234(1-2):124-30
– reference: 17438241 - Neurology. 2007 Apr 17;68(16 Suppl 2):S7-12
– reference: 20047900 - Brain. 2010 Feb;133(Pt 2):349-61
– reference: 21169067 - Clin Immunol. 2011 Mar;138(3):247-54
– reference: 17645239 - Neuropathology. 2007 Jun;27(3):245-56
– reference: 15589308 - Lancet. 2004 Dec 11-17;364(9451):2106-12
– reference: 11724044 - Acad Radiol. 2001 Sep;8(9):888-97
SSID ssj0032562
Score 2.5010273
Snippet Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO)....
Background Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis...
Abstract Background: Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for...
BACKGROUND: Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis...
Abstract Background Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for...
SourceID doaj
pubmedcentral
biomedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 184
SubjectTerms Adolescent
Adult
Aquaporin 4 - immunology
aquaporin-4
autoantibodies
Autoantibodies - blood
Autoantibodies - immunology
Autoantigens - immunology
Autoimmunity
biomarker
Child, Preschool
Complement Activation - immunology
complement mediated cytotoxicity
Development and progression
Experiments
Female
Humans
Immunoglobulin G
Immunoglobulin G - blood
Immunoglobulin G - immunology
Male
Middle Aged
Multiple sclerosis
Myelin proteins
Myelin Proteins - immunology
Myelin-Oligodendrocyte Glycoprotein
Myelitis, Transverse - blood
Myelitis, Transverse - immunology
Neuromyelitis optica
Neuromyelitis Optica - blood
Neuromyelitis Optica - immunology
Pediatrics
Physiological aspects
Proteins
Scanning electron microscopy
Statistical analysis
Studies
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k1oQT4gwSV07Th-iFNBVBVSOVGpN8vxo6y0JBWbPey_Z8bJrtZUiAtSTplxEnvGMx5n5jMhbz3rYuNAAtHFthZBptoYEWvuwNsb7lSIuKF_-U1eXImv1-31wVFfmBM2wQNPA3eqlWYxCO0UuHanuGudchA9BaP9gncBrS_4vF0wNdngBhw5n0ohOeiBETOoD9PydH-vhvBJ_1novir8U4bxv2usD7xVmUl54JrOH5GH85qSnk19eUzuxf4JuX85_zV_SjY46ac0cYp1DLgL299QGNNlN2AWIR0H-nOLlel0WC0hUo0IY-C3Y6Q3q60fMpgDEOHK-JeZd1yu6XCLW-HwpEBzUUwMNMxwnutn5Or8y_fPF_V83ELdSaXGOkjoh-k0Z7EJsNDxXnjw7pEntjBO805FJqVKi9TG5IPnJoHfS0q1LnjX-OY5OeqHPr4k1DWiiyHx2GEeKXA2XCWhWRJRM6VYRT4Wg25vJ2gNi2DXJQXmnUWRWRSZ1RZEVpEPOxFZPyOZ44EaK5sjGi3vNni_b7B7019ZP6HMiw_KN0An7ayT9l86WZF3qDEWbQR8mHdzqQMMDqJt2TOuDP5ONboiJwUnzG1fkI93Omdn27K2BmL2BgwxUOmeig0xXa6PwyazYKSND3gxKei-Q7AeXAgpeUVUobpFj0tKv_yRcccbPJVFt6_-xxAdkwd5d54hOMAJORp_beJrWN6N3Zs8k38DeUJOvA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k1oQT4gwSV04yR-iAMqiKpCKicq7c1y_FhWWpKlmz3sv2fG641qKpByiu3E9ow9M_bMN4S8tVXnawMU8Ma3ZeN4KJVqfMkMSHvFjHAeD_Qvv_OLq-bbvJ0n35xNcqs87Ilxo3aDxTPyUwWWClhTTH5a_y4xaRRerqYMGnfJPUQuQ48uMZ_srRqkOUtoPpXkp6B7M2AK1ZRgN8m_I9xXmWCK-P23d-kbYip3obwhk84fkYdJmaRne-o_Jnd8_4Tcv0zX5U_JFlf73j-cYgADHr_2CwqTuewGdB-k40B_7TAknQ6rJZioHvEL7G70dLHa2SGiOEAhPBH4MtYdlxs6rPEMHL7kaIyG8Y66hOO5eUauzr_--HJRpjwLZceFGEvHYRyqk6zytQMNx9rGglj3LFQzZSTrhK84F2EWWh-ss0wFEHhBiNY4a2pbPydH_dD7l4Sauum8C8x36EAKNWsmQiOr0HhZCVEV5GM26Xq9x9TQiHKdlwDxNZJMI8m01ECygnw4kEjbBGGOmTRWOpoykt9u8H5qcPjTP6t-RppnHYovhuuFTqtYSyEr7xppBOiZRjDTGmHAlHdK2hnrXEHeIcdo3BygY9akGAeYHITZ0mdMKLxHVbIgJ1lNWNQ2Kz4-8JxOm8pGT0ugIHQqxYboJ9f7YRuroImNH3ixZ9BpQKAIzhrOWUFExrrZiPOSfvkzAo7XmI5Ftq_-26lj8iCet1cY7n9CjsbrrX8NCtvYvYnL8g-gVERC
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3db9MwELdgSIgXxDfZBvIDErxkNI4T20IIDcQ0IZUnKu3NcvxRKoVktKm0_vfcuWmZtU3KU852Yt-d784fvyPknS0aXxrggDe-yrmrQ64U9zkzYO0VM8J5XNCf_qzPZ_zHRXXxPx3QOICrW0M7zCc1W7YnV383X0DhP0eFl_VHcKoZcFvxHAIiye-TB2CWBGrplO-3FEqw7WzE9rmlEoICMwbBIqbNSa6-t4nFisD-N6fva_YrPVt5zVidPSGPRy-Tnm7F4im557tn5OF03Ed_TtY4DWwPjlO82YDrst2cwigvmh7PFdKhp382eFed9u0CYlePwAZ2M3g6bze2j_AOQIQnImLGssNiRftLXByHlhyN12S8o24E-Fy9ILOz77--nedjAoa8qYUYcldDP1QjWeFLB66PtdyCvfcsFBNlJGuEL-pahEmofLDOMhXAEgYhKuOsKW35khx0fedfE2pK3ngXmG_wZCmULJkIXBaBe1kIUWTkUzLo-nILtqER_jqlgCZq5J5G7mmpgXsZOdmxSNsR2xxTbLQ6xjiyvlnhw77C7kt3Fv2KPE9-KL7ol3M9qreWQhbecWkEOKBGMFMZYSDGd0raCWtcRt6jxGiUY_gxa8bLDzA4iL-lT5lQuMGqZEaOk5Kg7TYhH-1kTu-URSuI4kuYmoFK91SsiAfoOt-vYxGMvbGBV1sB3XdoJ_cZEYnoJj1OKd3id0QiLzFPi6wO72zziDyKi_AFYgAck4NhufZvwIsbmrdRO_8BwSFGxw
  priority: 102
  providerName: Scholars Portal
Title Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
URI https://www.ncbi.nlm.nih.gov/pubmed/22204662
https://www.proquest.com/docview/921138328
https://www.proquest.com/docview/921560198
http://dx.doi.org/10.1186/1742-2094-8-184
https://pubmed.ncbi.nlm.nih.gov/PMC3278385
https://doaj.org/article/8781ed48a7514a72a5a7a523d98c02bd
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na9swFBdrC2OX0X1n7YIOg-3iLZJlfbBTM1rKIGWMFcIuQpbkLpDZZXEO-e_7nuxkdbudBiYHvyfF0pP0PqT3EyFvPStj7kAC0cUiE0FWmTEiZtyBtjfcqRAxoD-7kOeX4su8mP8Bi76zg8-0_AgmMwdZGpGBu6PFHjngAtQgOubTH9tFNwfNzbvcx465R_H5SwV3MtuXA4WUcPvvr8631NPw6OQtXXR2SB73RiQ96aT-hDyI9VPycNZvkz8ja5zl3blwiokLGHatryh04qJs8NggbRv6a4Op6LRZLsA1jYhb4DdtpFfLjW8SegMQ4UmAl4m3Xaxoc42xb6gp0JQFEwMNPX7n6jm5PDv9_vk86-9XyEqpVJsFCe0wpeYs5gEsG--FB3UeecUmxmleqsikVNWkKmLlg-emAkVXKVW44F3u8xdkv27q-IpQl4syhorHEg-OAmfOVSU0q0TUTCk2Ip8GnW6vOywNi-jWQwpMNIsisygyqy2IbEQ-bEVkfQ9djjdoLG1yYbS8X-D9rsD2n_7JOkWZDz4ovYAxaPvZa7XSLAahnQL70inuCqccuPDBaD_hZRiRdzhiLC4K8GHe9bkN0DkIr2VPuDK4f2r0iBwPOGEy-wH5aDvmbL-YrKwBJz2HlReodEfFgng-ro7NOrGga40VvOwG6K5BYABOhJR8RNRg6A5aPKTUi58JaDzHa1h08fq_hHdEHqU4PEMYgGOy3_5exzdgyLXlmOypuRqTg-npxddv4xQOgd-Z0OM0uW8At4tLng
linkProvider BioMedCentral
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviG_CBvgBBC9hjePEthBCG2zq2FohtEl7M47tdJW6pKypUP8o_kfu0qRamOBtUp7ijzi5y33Yd78j5LWNMh8boIA3Pgm5S_NQKe5DZkDbK2aE87ihPxylg1P-9Sw52yC_21wYDKtsZWItqF1pcY98R4GnAt4Uk59mP0MsGoWHq20FjRVXHPnlL_DY5h8PvwB53zB2sH_yeRA2RQXCLBWiCl3qnVWZZJGPHahza7kFHeZZHvWVkSwTPkpTkffzxOfWWaZykO65EIlx1sQ2hnlvkU0egyfTI5t7-6Nv31vRH4P9wBr8oEimO2DtM2BDxUPw1OTfOfXTjiqsKwZc1wtXFGM3aPOKFjy4T-415ivdXfHbA7Lhi4fk9rA5oH9EFihfVhHpFFMmcMO3GFMg3yQrMWCRViW9WGISPC2nE3CKPSIm2GXl6Xi6tGWNGwGNcNVQm3XfajKn5Qx33WEmR-v8G--oa5BD54_J6Y0Q4QnpFWXhnxFqYp55lzOfYcgq9IyZyLmMcu5lJEQUkA-dj65nKxQPjbja3RZgN40k00gyLTWQLCDvWxJp24CmY-2Oqa6dJ5leH_BuPaB90j-77iHNOwuqb5SXY93IDS2FjLzj0giwbI1gJjHCJCx2Sto-y1xA3iLHaBRHsDBrmqwK-DgI7KV3mVB4cqtkQLY7PUGM2E7zVstzuhFjc73-6QJC1604ECPzCl8u6i7o1OMET1cMun4hMD37PE1ZQESHdTtv3G0pJuc1xHmMBWBk8vy_i3pF7gxOhsf6-HB0tEXu1rv9EYINbJNedbnwL8BcrLKXzU9KyY-blgt_ABVdhC0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1Nb9Mw1BpDmrggvgkb4AMSXLI1jhPb4rQB1fjYhBBDExfL8UepKEm1pof-e95z0qphcELqoep7dur3_Ry_Z0Je2KzyuQEOeOOLlLsypEpxnzID3l4xI5zHDf2z8_L0gn-4LC53yLd1LUxPwSbEdo5AZKBLV8N3uF2PPotGHL7Yn0dzFzrdl-URxNcMGK94CrmR5DfITVEUAhX2y8n3tYXOwc2zrlCyQ-5b_vxlgj_K4GcD7xWb_F835Vu-bHjOcstxje-Q233ESY87EblLdnx9j-yd9e_U75MlmoTuEDnFKgfco60nFCg-rRo8Y0jbhv5aYd06bWZTyGM9Njmwq9bTyWxlm9jqAYDwieSMuO10QZs5bpTDTI7GkhnvqOubfS4ekIvxu69vTtP-Moa0KoVoU1fCOlQlWeZzB2GQtdyC7_csZCNlJKuEz8pShFEofLDOMhXAKwYhCuOsyW3-kOzWTe0fE2pyXnkXmK_wlClg5kwELrPAvcyEyBLyekB0Pe8ab2hshT2EgBRoZJlGlmmpgWUJOVyzSNu-zzletzHTMd-R5fUBrzYD1k_6J-oJ8nzwh-IPzdVE96qupZCZd1waAcGoEcwURhjI952SdsQql5CXKDEaLQhKsOkLIYA42ItLHzOh8GWrkgk5GGCC5tsBeH8tc7rXm4VWkNHnYKYBSjdQHIiH6WrfLCMK5uE4waNOQDcLgmhxxMuSJUQMRHew4iGknv6IXclzvLNFFk_-i3nPyd7nt2P96f35x31yK-7fZ9g-4IDstldL_xQCwLZ6FrX5N8euXGA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Complement+activating+antibodies+to+myelin+oligodendrocyte+glycoprotein+in+neuromyelitis+optica+and+related+disorders&rft.jtitle=Journal+of+neuroinflammation&rft.au=Mader%2C+Simone&rft.au=Gredler%2C+Viktoria&rft.au=Schanda%2C+Kathrin&rft.au=Rostasy%2C+Kevin&rft.date=2011-12-28&rft.eissn=1742-2094&rft.volume=8&rft.spage=184&rft_id=info:doi/10.1186%2F1742-2094-8-184&rft_id=info%3Apmid%2F22204662&rft.externalDocID=22204662
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon